Abstract
Evolutionary pressure for protein function leads to unavoidable sampling of conformational states that are at risk of misfolding and aggregation. The resulting tension between functional requirements and the risk of misfolding and/or aggregation in the evolution of proteins is becoming more and more apparent. One outcome of this tension is sensitivity to mutation, in which only subtle changes in sequence that may be functionally advantageous can tip the delicate balance toward protein aggregation. Similarly, increasing the concentration of aggregation-prone species by reducing the ability to control protein levels or compromising protein folding capacity engenders increased risk of aggregation and disease. In this Perspective, we describe examples that epitomize the tension between protein functional energy landscapes and aggregation risk. Each case illustrates how the energy landscapes for the at-risk proteins are sculpted to enable them to perform their functions and how the risks of aggregation are minimized under cellular conditions using a variety of compensatory mechanisms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jenik, M. et al. Protein frustratometer: a tool to localize energetic frustration in protein molecules. Nucleic Acids Res. 40, W348–W351 (2012).
Sutto, L., Latzer, J., Hegler, J.A., Ferreiro, D.U. & Wolynes, P.G. Consequences of localized frustration for the folding mechanism of the IM7 protein. Proc. Natl. Acad. Sci. USA 104, 19825–19830 (2007).
Zheng, W., Schafer, N.P. & Wolynes, P.G. Frustration in the energy landscapes of multidomain protein misfolding. Proc. Natl. Acad. Sci. USA 110, 1680–1685 (2013).
Knowles, T.P., Vendruscolo, M. & Dobson, C.M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384–396 (2014).
Uversky, V.N. Intrinsic disorder in proteins associated with neurodegenerative diseases. Front. Biosci. (Landmark Ed.) 14, 5188–5238 (2009).
Wright, P.E. & Dyson, H.J. Linking folding and binding. Curr. Opin. Struct. Biol. 19, 31–38 (2009).
Ma, B., Tsai, C.J., Haliloglu, T. & Nussinov, R. Dynamic allostery: linkers are not merely flexible. Structure 19, 907–917 (2011).
Kalodimos, C.G. Protein function and allostery: a dynamic relationship. Ann. NY Acad. Sci. 1260, 81–86 (2012).
Motlagh, H.N., Wrabl, J.O., Li, J. & Hilser, V.J. The ensemble nature of allostery. Nature 508, 331–339 (2014).
Tóth-Petróczy, A. & Tawfik, D.S. The robustness and innovability of protein folds. Curr. Opin. Struct. Biol. 26, 131–138 (2014).
Tartaglia, G.G., Pechmann, S., Dobson, C.M. & Vendruscolo, M. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem. Sci. 32, 204–206 (2007).
De Baets, G. et al. An evolutionary trade-off between protein turnover rate and protein aggregation favors a higher aggregation propensity in fast degrading proteins. PLOS Comput. Biol. 7, e1002090 (2011).
Monsellier, E. & Chiti, F. Prevention of amyloid-like aggregation as a driving force of protein evolution. EMBO Rep. 8, 737–742 (2007).
Kim, Y.E., Hipp, M.S., Bracher, A., Hayer-Hartl, M. & Hartl, F.U. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 82, 323–355 (2013).
Pastore, A. & Temussi, P.A. The two faces of Janus: functional interactions and protein aggregation. Curr. Opin. Struct. Biol. 22, 30–37 (2012).
Chen, L. et al. Structural instability tuning as a regulatory mechanism in protein-protein interactions. Mol. Cell 44, 734–744 (2011).
Hong, W., Wu, Y.E., Fu, X. & Chang, Z. Periplasmic protein HdeA exhibits chaperone-like activity exclusively within stomach pH range by transforming into disordered conformation. J. Biol. Chem. 280, 27029–27034 (2005).
Foit, L., George, J.S., Zhang, B.W., Brooks, C.L. III & Bardwell, J.C. Chaperone activation by unfolding. Proc. Natl. Acad. Sci. USA 110, E1254–E1262 (2013).
Gianni, S., Camilloni, C., Giri, R, Toto, A., Bonetti, D., Morrone, A., Sormanni, P., Brunori, M., & Vendruscolo, M. Understanding the frustration arising from the competition between function, misfolding, and aggregation in a globular protein. Proc. Natl. Acad. Sci. USA 10.1073/pnas.1405233111 (17 September 2014).
Bernlohr, D.A., Simpson, M.A., Hertzel, A.V. & Banaszak, L.J. Intracellular lipid-binding proteins and their genes. Annu. Rev. Nutr. 17, 277–303 (1997).
Ferrolino, M.C., Zhuravleva, A., Budyak, I.L., Krishnan, B. & Gierasch, L.M. Delicate balance between functionally required flexibility and aggregation risk in a β-rich protein. Biochemistry 52, 8843–8854 (2013).
Budyak, I.L. et al. Early folding events protect aggregation-prone regions of a β-rich protein. Structure 21, 476–485 (2013).
Banaszak, L. et al. Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv. Protein Chem. 45, 89–151 (1994).
Lücke, C., Zhang, F., Ruterjans, H., Hamilton, J.A. & Sacchettini, J.C. Flexibility is a likely determinant of binding specificity in the case of ileal lipid binding protein. Structure 4, 785–800 (1996).
Hodsdon, M.E. & Cistola, D.P. Ligand binding alters the backbone mobility of intestinal fatty acid-binding protein as monitored by 15N NMR relaxation and 1H exchange. Biochemistry 36, 2278–2290 (1997).
Eberini, I. et al. Conformational and dynamics changes induced by bile acids binding to chicken liver bile acid binding protein. Proteins 71, 1889–1898 (2008).
Cai, J. et al. Solution structure and backbone dynamics of human liver fatty acid binding protein: fatty acid binding revisited. Biophys. J. 102, 2585–2594 (2012).
Krishnan, V.V., Sukumar, M., Gierasch, L.M. & Cosman, M. Dynamics of cellular retinoic acid binding protein I on multiple time scales with implications for ligand binding. Biochemistry 39, 9119–9129 (2000).
Storch, J. & McDermott, L. Structural and functional analysis of fatty acid-binding proteins. J. Lipid Res. 50 Suppl, S126–S131 (2009).
Falomir-Lockhart, L.J., Laborde, L., Kahn, P.C., Storch, J. & Corsico, B. Protein-membrane interaction and fatty acid transfer from intestinal fatty acid–binding protein to membranes. Support for a multistep process. J. Biol. Chem. 281, 13979–13989 (2006).
Budhu, A., Gillilan, R. & Noy, N. Localization of the RAR interaction domain of cellular retinoic acid binding protein-II. J. Mol. Biol. 305, 939–949 (2001).
Clark, P.L., Liu, Z.P., Rizo, J. & Gierasch, L.M. Cavity formation before stable hydrogen bonding in the folding of a β-clam protein. Nat. Struct. Biol. 4, 883–886 (1997).
Clark, P.L., Liu, Z.P., Zhang, J. & Gierasch, L.M. Intrinsic tryptophans of CRABPI as probes of structure and folding. Protein Sci. 5, 1108–1117 (1996).
Clark, P.L., Weston, B.F. & Gierasch, L.M. Probing the folding pathway of a β-clam protein with single-tryptophan constructs. Fold. Des. 3, 401–412 (1998).
Eyles, S.J. & Gierasch, L.M. Multiple roles of prolyl residues in structure and folding. J. Mol. Biol. 301, 737–747 (2000).
Gunasekaran, K., Hagler, A.T. & Gierasch, L.M. Sequence and structural analysis of cellular retinoic acid-binding proteins reveals a network of conserved hydrophobic interactions. Proteins 54, 179–194 (2004).
Gettins, P.G.W. Serpin structure, mechanism, and function. Chem. Rev. 102, 4751–4804 (2002).
Dementiev, A., Dobo, J. & Gettins, P.G.W. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of α1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 281, 3452–3457 (2006).
Huntington, J.A., Read, R.J. & Carrell, R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923–926 (2000).
Gooptu, B. & Lomas, D.A. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78, 147–176 (2009).
Mottonen, J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355, 270–273 (1992).
Klieber, M.A., Underhill, C., Hammond, G.L. & Muller, Y.A. Corticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered release. J. Biol. Chem. 282, 29594–29603 (2007).
Qi, X., Chan, W.L., Read, R.J., Zhou, A. & Carrell, R.W. Temperature-responsive release of thyroxine and its environmental adaptation in Australians. Proc. Biol. Sci. 281, 20132747 (2014).
Zhou, A., Wei, Z., Read, R.J. & Carrell, R.W. Structural mechanism for the carriage and release of thyroxine in the blood. Proc. Natl. Acad. Sci. USA 103, 13321–13326 (2006).
Baek, J.-H., Yang, W.S., Lee, C. & Yu, M.-H. Functional unfolding of α1-antitrypsin probed by hydrogen-deuterium exchange coupled with mass spectrometry. Mol. Cell. Proteomics 8, 1072–1081 (2009).
Carrell, R.W., Stein, P.E., Fermi, G. & Wardell, M.R. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2, 257–270 (1994).
Trelle, M.B., Madsen, J.B., Andreasen, P.A. & Jørgensen, T.J.D. Local transient unfolding of native state PAI-1 associated with serpin metastability. Angew. Chem. Int. Ed. Engl. 53, 9751–9754 (2014).
Zhou, A. et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 468, 108–111 (2010).
Marszal, E. & Shrake, A. Serpin crystal structure and serpin polymer structure. Arch. Biochem. Biophys. 453, 123–129 (2006).
Zhang, Q., Law, R.H.P., Bottomley, S.P., Whisstock, J.C. & Buckle, A.M. A structural basis for loop C-sheet polymerization in serpins. J. Mol. Biol. 376, 1348–1359 (2008).
Yamasaki, M., Li, W., Johnson, D.J.D. & Huntington, J.A. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455, 1255–1258 (2008).
Yamasaki, M., Sendall, T.J., Pearce, M.C., Whisstock, J.C. & Huntington, J.A. Molecular basis of a1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep. 12, 1011–1017 (2011).
Dolmer, K. & Gettins, P.G. How the serpin a1-proteinase inhibitor folds. J. Biol. Chem. 287, 12425–12432 (2012).
Stein, P.E. & Carrell, R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2, 96–113 (1995).
Lomas, D.A. & Carrell, R.W. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3, 759–768 (2002).
Davis, R.L. et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 401, 376–379 (1999).
Hagen, M.C. et al. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene. Brain Pathol. 21, 575–582 (2011).
Miranda, E. et al. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum. Mol. Genet. 17, 1527–1539 (2008).
Perlmutter, D.H. α-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease–associated protein aggregates. Annu. Rev. Med. 62, 333–345 (2011).
Schipanski, A. et al. The lectin OS-9 delivers mutant neuroserpin to endoplasmic reticulum associated degradation in familial encephalopathy with neuroserpin inclusion bodies. Neurobiol. Aging 35, 2394–2403 (2014).
Gelling, C.L., Dawes, I.W., Perlmutter, D.H., Fisher, E.A. & Brodsky, J.L. The endosomal protein-sorting receptor sortilin has a role in trafficking α-1 antitrypsin. Genetics 192, 889–903 (2012).
Nickson, A.A., Wensley, B.G. & Clarke, J. Take home lessons from studies of related proteins. Curr. Opin. Struct. Biol. 23, 66–74 (2013).
Chiti, F. et al. Detection of two partially structured species in the folding process of the amyloidogenic protein β2-microglobulin. J. Mol. Biol. 307, 379–391 (2001).
Jahn, T.R., Parker, M.J., Homans, S.W. & Radford, S.E. Amyloid formation under physiological conditions proceeds via a native-like folding intermediate. Nat. Struct. Mol. Biol. 13, 195–201 (2006).
Wright, C.F., Teichmann, S.A., Clarke, J. & Dobson, C.M. The importance of sequence diversity in the aggregation and evolution of proteins. Nature 438, 878–881 (2005).
Feige, Y. & Buchner, J. Principles and engineering of antibody folding and assembly. Biochim. Biophys. Acta doi:10.1016/j.bbapap.2014.06.004 (13 June 2014).
Eichner, T. & Radford, S.E. Understanding the complex mechanisms of β2-microglobulin amyloid assembly. FEBS J. 278, 3868–3883 (2011).
Chiti, F. et al. A partially structured species of β2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J. Biol. Chem. 276, 46714–46721 (2001).
Kameda, A. et al. Nuclear magnetic resonance characterization of the refolding intermediate of β2-microglobulin trapped by non-native prolyl peptide bond. J. Mol. Biol. 348, 383–397 (2005).
Eichner, T., Kalverda, A.P., Thompson, G.S., Homans, S.W. & Radford, S.E. Conformational conversion during amyloid formation at atomic resolution. Mol. Cell 41, 161–172 (2011).
Eichner, T. & Radford, S.E. A generic mechanism of β2-microglobulin amyloid assembly at neutral pH involving a specific proline switch. J. Mol. Biol. 386, 1312–1326 (2009).
Esposito, G. et al. Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci. 9, 831–845 (2000).
White, H.E. et al. Globular tetramers of β2-microglobulin assemble into elaborate amyloid fibrils. J. Mol. Biol. 389, 48–57 (2009).
Su, Y. et al. Secondary structure in the core of amyloid fibrils formed from human β2m and its truncated variant δN6. J. Am. Chem. Soc. 136, 6313–6325 (2014).
Karamanos, T.K., Kalverda, A.P., Thompson, G.S. & Radford, S.E. Visualization of transient protein-protein interactions that promote or inhibit amyloid assembly. Mol. Cell 55, 214–226 (2014).
Zijlstra, M. et al. β2-microglobulin deficient mice lack CD4–8+ cytolytic T cells. Nature 344, 742–746 (1990).
Ricagno, S., Raimondi, S., Giorgetti, S., Bellotti, V. & Bolognesi, M. Human β2 microglobulin W60V mutant structure: implications for stability and amyloid aggregation. Biochem. Biophys. Res. Commun. 380, 543–547 (2009).
Esposito, G. et al. The controlling roles of Trp60 and Trp95 in β2-microglobulin function, folding and amyloid aggregation properties. J. Mol. Biol. 378, 887–897 (2008).
Valleix, S. et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N. Engl. J. Med. 366, 2276–2283 (2012).
Mangione, P.P. et al. Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and a-crystallin. J. Biol. Chem. 288, 30917–30930 (2013).
Halabelian, L. et al. Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin. J. Biol. Chem. 289, 3318–3327 (2014).
Corlin, D.B. & Heegaard, N.H. β2-microglobulin amyloidosis. Subcell. Biochem. 65, 517–540 (2012).
Raimondi, S. et al. The two tryptophans of β2-microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressure. BMC Evol. Biol. 11, 159 (2011).
Zoghbi, H.Y. & Orr, H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 284, 7425–7429 (2009).
Orr, H.T. Cell biology of spinocerebellar ataxia. J. Cell Biol. 197, 167–177 (2012).
Matos, C.A., de Macedo-Ribeiro, S. & Carvalho, A.L. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog. Neurobiol. 95, 26–48 (2011).
Paulson, H. Machado-Joseph disease/spinocerebellar ataxia type 3. Handb. Clin. Neurol. 103, 437–449 (2012).
Almeida, B., Fernandes, S., Abreu, I.A. & Macedo-Ribeiro, S. Trinucleotide repeats: a structural perspective. Front Neurol. 4, 76 (2013).
Nicastro, G. et al. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc. Natl. Acad. Sci. USA 102, 10493–10498 (2005).
Fiumara, F., Fioriti, L., Kandel, E.R. & Hendrickson, W.A. Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell 143, 1121–1135 (2010).
Pelassa, I. et al. Association of polyalanine and polyglutamine coiled coils mediates expansion disease-related protein aggregation and dysfunction. Hum. Mol. Genet. 23, 3402–3420 (2014).
Doss-Pepe, E.W., Stenroos, E.S., Johnson, W.G. & Madura, K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol. Cell. Biol. 23, 6469–6483 (2003).
Wang, G., Sawai, N., Kotliarova, S., Kanazawa, I. & Nukina, N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 9, 1795–1803 (2000).
Zhong, X. & Pittman, R.N. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Hum. Mol. Genet. 15, 2409–2420 (2006).
Nicastro, G. et al. Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites. Biopolymers 91, 1203–1214 (2009).
Nicastro, G. et al. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS ONE 5, e12430 (2010).
Ellisdon, A.M., Pearce, M.C. & Bottomley, S.P. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J. Mol. Biol. 368, 595–605 (2007).
Ellisdon, A.M., Thomas, B. & Bottomley, S.P. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J. Biol. Chem. 281, 16888–16896 (2006).
Gales, L. et al. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J. Mol. Biol. 353, 642–654 (2005).
Masino, L. et al. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J. Mol. Biol. 344, 1021–1035 (2004).
Hübener, J. et al. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain 134, 1925–1942 (2011).
Masino, L. et al. The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils. Biophys. J. 100, 2033–2042 (2011).
de Chiara, C., Menon, R.P., Kelly, G. & Pastore, A. Protein-protein interactions as a strategy towards protein-specific drug design: the example of ataxin-1. PLoS ONE 8, e76456 (2013).
Kleywegt, G.J. et al. Crystal structures of cellular retinoic acid binding proteins I and II in complex with all-trans-retinoic acid and a synthetic retinoid. Structure 2, 1241–1258 (1994).
Corsico, B., Cistola, D.P., Frieden, C. & Storch, J. The helical domain of intestinal fatty acid binding protein is critical for collisional transfer of fatty acids to phospholipid membranes. Proc. Natl. Acad. Sci. USA 95, 12174–12178 (1998).
Dementiev, A., Simonovic, M., Volz, K. & Gettins, P. Canonical inhibitor-like interactions explain reactivity of a1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 278, 37881–37887 (2003).
McCoy, A.J., Pei, X.Y., Skinner, R., Abrahams, J.P. & Carrell, R.W. Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J. Mol. Biol. 326, 823–833 (2003).
Tysoe-Calnon, V.A., Grundy, J.E. & Perkins, S.J. Molecular comparisons of the β2-microglobulin-binding site in class I major-histocompatibility-complex α-chains and proteins of related sequences. Biochem. J. 277, 359–369 (1991).
Acknowledgements
We thank our many collaborators and co-authors whose experiments and ideas have contributed to our work. We also recognize that all relevant examples and references cannot be included in a short perspective such as this, and we apologize to those whose contributions we have omitted. We acknowledge, with thanks, funding from the National Institutes of Health (grants GM027616 and GM101644 to L.M.G., GM094848 to L.M.G. and A.G. and GM060418 to A.G.); the Medical Research Council (grant U117584256 to A.P.) and the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013; 322408) and the Wellcome Trust (WT092896MA to S.E.R.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gershenson, A., Gierasch, L., Pastore, A. et al. Energy landscapes of functional proteins are inherently risky. Nat Chem Biol 10, 884–891 (2014). https://doi.org/10.1038/nchembio.1670
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1670
This article is cited by
-
Quantum model for understanding protein misfolding behavior—phase diagram and manual intervention
Science China Physics, Mechanics & Astronomy (2021)
-
Mechanistic insights into the deleterious roles of Nasu-Hakola disease associated TREM2 variants
Scientific Reports (2020)
-
Network mapping of the conformational heterogeneity of SOD1 by deploying statistical cluster analysis of FTIR spectra
Cellular and Molecular Life Sciences (2019)
-
Structural basis for cross-reactivity and conformation fluctuation of the major beech pollen allergen Fag s 1
Scientific Reports (2018)
-
Probing Molecular Basis for Constructing Interface Bionanostructures
Topics in Catalysis (2018)